Close Menu

irritable bowel syndrome

Norwegian molecular diagnostics firm Genetic Analysis announced two new developments last week. The first was the appointment of Kari Stenerson, a former Axis-Shield marketing director, as its new CEO.

Researchers led by a group at Beth Israel Deaconess Medical Center have identified a genetic marker associated with the placebo effect in patients with irritable bowel syndrome.

The exclusive sales and marketing agreement covers gene expression tests for inflammatory bowel disease and irritable bowel syndrome.

The first version of the sequencer, about to enter beta-testing, will cost around $250,000 and will be able to generate several gigabases of data in a 5.5-hour run with $250 in consumables costs per gigabase. That price is expected to fall to as little as $2 with later generations.

Battelle Ventures, MIT, Hepragen, Wayne State University, Defyrus, UK Ministry of Defence, Columbia U, Intelligent Bio-Systems, Kauffman Foundation

Short Reads: Feb 24, 2009

Premium

Intelligent Bio-Systems, Norwich Ventures, National Human Genome Research Institute, Floragenex, National Center for Genome Resources, Decode Genetics, DNAStar, Infogen

IBS has kept a relatively low profile the past couple of years, but it plans to get prototype sequencing systems into the hands of early-access customers as early as the first quartyer of this year.

Pages

23andMe is offering early customers re-testing on newer chips for a fee, Wired reports.

He Jiankui is no longer affiliated with Direct Genomics Biotechnology, the single molecule sequencing company he founded, Nikkei Asian Review reports.

Newsweek writes about the hopes for precision medicine in cancer, but also challenges getting it to patients.

In Genome Research this week: genomic architecture of glioblastoma, predictive computational approach to estimate SNP fitness, and more.